2024
Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer
Ríos-Hoyo A, Cobain E, Huppert L, Beitsch P, Buchholz T, Esserman L, van 't Veer L, Rugo H, Pusztai L. Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor–Positive Human Epidermal Growth Factor 2–Negative Breast Cancer. Journal Of Clinical Oncology 2024, 42: 2632-2636. PMID: 38593393, DOI: 10.1200/jco.23.02614.Peer-Reviewed Original Research
2023
Associations amongst genes, molecules, cells, and organs in breast cancer metastasis
Nathanson S, Dieterich L, Zhang X, Chitale D, Pusztai L, Reynaud E, Wu Y, Ríos-Hoyo A. Associations amongst genes, molecules, cells, and organs in breast cancer metastasis. Clinical & Experimental Metastasis 2023, 1-21. PMID: 37688650, DOI: 10.1007/s10585-023-10230-w.Peer-Reviewed Original ResearchBreast cancer metastasisBreast cancerCancer metastasisOutcomes of patientsAnti-tumor immunityHope of cureAggressive therapyMultiple metastasesAggressive treatmentBone metastasesLymph nodesSystemic metastasesMorphologic subtypesClinical oncologistsMetastasisInternal visceraAssists cliniciansLymphatic endothelial cellsPatientsEndothelial cellsHealth SymposiumBasic scientistsMolecular expressionCancerMolecular aspects
2022
Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
Ríos-Hoyo A, Moliner L, Arriola E. Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge. Cancers 2022, 14: 1931. PMID: 35454838, PMCID: PMC9027936, DOI: 10.3390/cancers14081931.Peer-Reviewed Original ResearchMechanisms of resistanceNon-small cell lung cancerEGFR-mutant tumorsPercentage of non-small cell lung cancerCell lung cancerMultiple mechanisms of resistanceEGFR tumorsPotential therapeutic strategyClinical benefitToxicity profileTreatment optionsLung cancerFrequent alterationsTherapeutic strategiesAcquired mechanismsOsimertinibTumorMultiple mechanismsTreatmentEGFRIncreased useCancer91P Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer
Rocha P, Rodrigo M, Moliner L, Ríos-Hoyo A, Masfarré L, Navarro-Gorro N, Menendez S, Taus A, Rodríguez A, Aguiló R, Belda J, Del Rey-Vergara R, Galindo M, Comerma L, Arriola E. 91P Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer. Annals Of Oncology 2022, 33: s75. DOI: 10.1016/j.annonc.2022.02.101.Peer-Reviewed Original Research